Clinical Trials

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05283720 2026-05-06

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06149286 2026-05-06

OLYMPIA-5

Phase 3 Recruiting

470 enrolled

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT04712097 2026-05-05

Celestimo

478 enrolled

Lymphoma, Follicular, Recurrence

NCT05533775 2026-05-04

iMATRIX GLO

Phase 1/2 Recruiting

65 enrolled

Recurrence

NCT04989621 2026-04-23

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

32 enrolled

Lymphoma, Follicular, Recurrence

NCT05888493 2026-04-17

LEDA

109 enrolled

Lymphoma, Follicular, Recurrence

NCT05498220 2026-04-16

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Terminated

5 enrolled 13 charts

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06824701 2026-04-06

TARZAN

Phase 1 Suspended

24 enrolled

Recurrence, Lymphoma, B-Cell

NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence

NCT03458260 2026-03-10

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

74 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04268277 2026-02-27

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Phase 2 Terminated

22 enrolled 20 charts

Phase 1/2 Active not recruiting

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT04421560 2026-02-20

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Phase 1/2 Recruiting

37 enrolled

Neoplasms, Recurrence

NCT03930953 2026-02-19

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

438 enrolled

Lymphoma, Non-Hodgkin, Recurrence

NCT06644183 2026-02-11

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Phase 1/2 Recruiting

64 enrolled

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06097364 2026-02-06

OLYMPIA-2

733 enrolled

Lymphoma, Follicular, Recurrence

NCT02390869 2025-12-02

FIL_RENOIR12

128 enrolled

Lymphoma, Follicular, Recurrence

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07001540 2025-06-19

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

130 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06414148 2025-06-05

EpLCART

40 enrolled

Lymphoma, Recurrence, Neoplasm, Residual

NCT04464798 2025-04-29

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Phase 1 Terminated

62 enrolled

Lymphoma, Recurrence

NCT05578976 2025-01-23

EPCORE DLBCL-2

900 enrolled

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03630042 2024-11-07

PembroWM

17 enrolled 7 charts

Waldenstrom Macroglobulinemia, Recurrence

NCT01199575 2024-08-15

Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

30 enrolled 12 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01134575 2024-07-16

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

90 enrolled 10 charts

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02384954 2024-07-03

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Phase 1/2 Terminated

43 enrolled 15 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02600897 2023-12-26

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Completed

114 enrolled 34 charts

Lymphoma, Follicular, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05940051 2023-07-11

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

35 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04136756 2023-06-15

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

30 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT04113226 2023-02-08

Relyage

114 enrolled

LymphoidSarcoma

Recurrence, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT03422523 2022-08-22

ARGO

Phase 2 Terminated

53 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04796922 2022-07-18

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT01321541 2021-11-19

PIX-R

Phase 3 Completed

312 enrolled 16 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03189836 2021-10-11

Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

Phase 1 Terminated

26 enrolled

Lymphoma, Recurrence

NCT04994626 2021-08-06

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

20 enrolled

Lymphoma, Recurrence

NCT02187133 2021-04-23

Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

10 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence

NCT01956695 2020-12-17

REVRI

45 enrolled

Lymphoma, Recurrence

NCT02752204 2020-11-05

TORCH

36 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01542918 2020-08-11

Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

14 enrolled

Lymphoma, Recurrence, Intraocular Lymphoma

NCT02481297 2020-05-28

Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

7 enrolled 11 charts

Leukemia, Leukemia, Lymphoid, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04361409 2020-04-28

Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

10 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT02776813 2020-03-31

Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma

34 enrolled

Lymphoma, Recurrence

NCT01611090 2020-03-03

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3 Completed

578 enrolled 21 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04279938 2020-02-21

A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL

Phase 1 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02267915 2020-01-27

MAN2

36 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT00785330 2020-01-13

Allo-hNHL (FluBuCy)

84 enrolled

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT01576588 2019-12-27

Rituximab in Pretreated Elderly or Unfit B-CLL Patients

25 enrolled 9 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2/3 Completed

111 enrolled 20 charts

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01729104 2019-10-22

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Phase 1 Terminated

18 enrolled